Table 2.

Overall distribution of levels in the EQ-5D-5L dimensions.

Problems/dimensions	N	Mobility	Self-care	Usual activities	Pain/discomfort	Anxiety/depression	EQ-VAS
All patients
Mean (SD)	1,106	1.95 (1.16)	1.71 (1.15)	2.39 (1.25)	1.70 (0.83)	1.80 (0.85)	68.23 (22.92)
Distribution
None (1)		48.8%	63.9%	29.3%	50.2%	42.0%	–
Slight (2)		24.3%	16.6%	30.3%	33.2%	40.9%	–
Moderate (3)		15.1%	10.1%	22.3%	13.7%	12.9%	–
Severe (4)		7.1%	3.7%	9.1%	2.6%	3.3%	–
Extreme (5)		4.7%	5.7%	9.1%	0.4%	0.9%	–
Progression status, mean (SD)
Non-progressed	690	1.71 (0.98)	1.46 (0.89)	2.15 (1.13)	1.6 (0.76)	1.7 (0.81)	73.77 (19)
Progressed	307	2.37 (1.35)	2.15 (1.4)	2.85 (1.33)	1.89 (0.94)	2.01 (0.9)	56.8 (25.85)
Current treatments, mean (SD)
TTFields only	431	1.84 (1.16)	1.59 (1.09)	2.23 (1.26)	1.61 (0.8)	1.73 (0.81)	71.38 (22.54)
TTFields + others	640	2.01 (1.16)	1.78 (1.17)	2.47 (1.22)	1.76 (0.84)	1.84 (0.86)	66.28 (22.78)
Time from diagnosis, mean (SD)
0–15 months	595	1.99 (1.2)	1.79 (1.21)	2.51 (1.29)	1.71 (0.83)	1.85 (0.89)	66.32 (23.69)
>15 months	489	1.9 (1.12)	1.61 (1.08)	2.25 (1.18)	1.69 (0.83)	1.76 (0.8)	70.12 (21.99)

Lower scores indicate less impairment and higher scores more impairment in health-related quality of life (HRQoL) for the EQ-5D subscales of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For EQ-VAS, higher values indicate improved self-rated health and lower values indicate worse self-rated health.

EQ-VAS, EuroQol’s visual analogue scale; TTFields, tumor treating fields.